, Chi-Neu Tsai 1, 3 , Yun-Shien Lee 3, 4 , Shu-Fen Chu 2 , Ning-Hung Chen 2, 5 O bstructive sleep apnea (OSA) syndrome is characterized by episodes of complete or partial pharyngeal obstruction during sleep, together with symptoms of daytime sleepiness or frequently altered cardiopulmonary function. [1] Epidemiologic studies have shown that this disease affects 2-4% of middle-aged adults; however, only a small proportion of these individuals have been clinically diagnosed because of a lack of awareness of the existence of sleep apnea. [2] This is a point of concern as patients with OSA tend to have an increased risk of diurnal hypertension, nocturnal dysrhythmias, pulmonary hypertension, right and left ventricular failure, myocardial infarction, and stroke. [3] [4] [5] [6] [7] In addition, patients with OSA have an increased risk of motor vehicle accidents (at least sevenfold greater than normal), which strongly suggests that sleep apnea affects not only the patient's quality of life but also the safety of the general public.
The severity of OSA is determined based on assessments of nasal flow, specifically the number of episodes of apnea and hypopnea per hour. The degree of hypoxic stress resulting from OSA can also be determined by examining changes in arterial oxygen desaturation during sleep. A full night of polysomnography (PSG), conducted by a technologist in a sleep laboratory, has traditionally been regarded as the gold standard for diagnosing sleep apnea. PSG is performed to confirm the presence of upper airway closure during sleep and to assess the patient's level of risk. [11] The severity of sleep apnea is indicated by the number of episodes of apnea and hypopnea per hour of sleep [the apnea hypopnea index (AHI)] or the respiratory disturbance index (RDI). Most patients with sleep apnea have an RDI > 5. [12] Several factors have been reported to be associated with the pathogenesis of OSA, including age, sex, obesity, craniofacial structure, alcohol and other drug use, and ethnicity. [2, [13] [14] [15] [16] [17] [18] Recent evidence suggests that ethnic factors also play another role in the pathogenesis of OSA, although sex and craniomandibular factors also contribute to OSA syndrome. In far eastern Asia, patients with OSA are less obese, but have a higher risk of developing severe OSA than Caucasians. [19] Therefore, obesity might be a less significant risk factor for OSA in Asia given that most Asian patients with OSA are less obese than their Caucasians counterparts. [20] Besides ethnic factors, chronically elevated proinflammatory mediators have been detected in patients with OSA. [21, 22] It has been postulated that cardiovascular complications are related to the inflammatory process induced by activation of proinflammatory mediators. [23] Selectively activated inflammatory pathways [e.g., the transcription factor nuclear factor kappa B (NF B) pathway] contribute to endothelial dysfunction and cardiovascular disease. [24] [25] [26] [27] Taken together, the results of these studies indicate that OSA is a complicated disease involving several pathogenic mechanisms.
Microarray technology provides a high-throughput means of identifying differentially expressed genes, and thus potential pathogenic mechanisms, in patients with OSA. Differential expression of genes was found in studies using peripheral blood mononuclear cell (PBMC) samples from patients with OSA and non-obese children with OSA using the Affymetrix U133A chip. [28, 29] In these studies, several candidate genes were identified, including heme oxygenase 1, superoxide dismutase 1 and 2, and catalase. The identification of these genes implicated the activation of several mechanisms to modulate and adapt to increased reactive oxygen species (ROS) generated as a consequence of the frequent episodes of intermittent hypoxia/reoxygenation in patients with OSA. [28] Patients in the aforementioned study had a mean body mass index (BMI) of 35.5 ± 1.29 kg/m 2 . Asian patients with OSA have lower BMI, but severe RDI. [18] Therefore, we used the Affymetrix U133A gene chip to globally analyze differential transcriptome expression in PBMC samples from Asian patients with OSA and nonapneic control participants. Peripheral blood from patients with OSA (n = 6) or controls (n = 3) was collected for use as the training set after overnight PSG. The gene expression profile was analyzed using the Affymetrix U133A gene chip. We enrolled a further 25 patients with OSA and 24 control participants without apnea as a validation set to verify microarray data using real-time polymerase chain reaction (PCR). The gene signature, involved pathways, and possible markers of OSA were determined and are discussed in this report.
METHODS

Patients and control participants
Both patients and control participants were recruited from the Sleep Center of Chang Gung Memorial Hospital (CGMH). Full PSG monitoring was performed using a Somnologica Sleep System (Medicare, Reykjavík, Iceland) with simultaneous EEG, electro-oculography, electromyography, and ECG. Surface electrodes were used to record two channels of EEG (C3A2, C4A1), right and left electro-oculography, and submental electromyography. Ventilatory flow at the nose and mouth was measured with thermistors. Ventilatory movements of the chest and abdomen were monitored using inductive plethysmography bands. Arterial oxygen saturation (SaO 2 ) was measured transcutaneously using fingertip pulse oximetry. Apnea was defined as continuous cessation of airflow for ≥ 10 s, whereas hypopnea was defined as a reduction in airflow for ≥ 10 s with oxygen desaturation ≥ 4%, or an EEG arousal from sleep. Apneas were classified as obstructive, mixed, or central according to the diagnostic criteria of the American Academy of Sleep Medicine. [1] The RDI was determined by dividing the number of respiratory events by the estimated hours of sleep. PSG was performed from 10 p.m. to 6 a.m.
Inclusion criteria were: age from 18 to 75 years, RDI > 5, and normal health in the week before the study. Control participants without apnea were recruited from participants who were referred for PSG monitoring because of other sleep problems. These participants had an RDI < 5 and did not exhibit snoring as a primary symptom. Individuals who had systemic infections at the time of the study or within 2 weeks before the study were excluded.
The study protocol was approved by the Ethical Review Committee of CGMH, and written informed consent was obtained from all participants.
RNA extraction
Blood samples were collected at 6 a.m. after PSG and overnight fasting. All samples were stored in PAXgene RNA Blood Tubes for 4 h before RNA extraction. Extraction of total RNA was performed in accordance with the manufacturer's instruction (PAXgene Blood RNA System, PreAnalytiX, Hombrechtikon, Switzerland). The quality and quantity of RNA was analyzed using a Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA). Gene expression profiles were analyzed using a human U133A GeneChip following the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA).
Microarray data processing
Total RNA (1 μg) isolated from peripheral blood was converted to cRNA using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA), and 25 μg of labeled probe was hybridized to Affymetrix U133A arrays. Gene expression data were generated and normalized using the robust multichip average method [30] with RMAEXPRESS (http:// stat-www.berkeley.edu/~bolstad/RMAExpress/RMAExpress. html). The differential expression of genes between patients with OSA and control participants was selected with the fold-change > 2 and p < 0.05 (Mann-Whitney U test). A total of 56 genes were selected and hierarchical cluster analysis was performed. Gene cluster 3.0 and Treeview [31] (bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/), with average-linkage clustering algorithms, were used for visualization. In the resulting expression map, increased gene expression was indicated by red color, whereas decreased gene expression was indicated by green color. Black color indicated that expression was the same in patients with OSA and control participants [ Figure 1 ].
Pathway prediction analysis
Network analyses of differentially expressed genes were performed using MetaCore Analytical Suite (GeneGo Inc., St. Joseph, MI, USA, http://www.genego.com). [32, 33] MetaCore is a web-based computational platform designed for systems biology and drug discovery. It includes a curate database of human protein interactions and metabolism; thus, it is useful for analyzing a cluster of genes in the context of regulatory networks and signaling pathways. For the network analysis of a group of genes, MetaCore can be used to calculate the statistical significance (p value) based on the probability of assembly from a random set of nodes (genes) of the same size as the input list. [33] The 56 differentially expressed genes between patients with OSA and control participants were entered in to MetaCore analysis on the basis of Dijkstra's "shortest path" algorithm. A p value was calculated ranking the pathways according to saturation with the objects from the differential gene list.
Real-time reverse transcriptase polymerase chain reaction
A total of 1 μg of amplified anti-sense RNA (aRNA) (pre-treated with DNase) was mixed with reverse transcriptase (Roche, Mannheim, Germany) and oligo-dT primers to generate 25 mL of first strand cDNA. Real-time quantitative (RTQ)-PCR was performed using 0.5 μL of the first strand cDNA synthesis mixture as a template with TaqMan primer/probe sets (Assay-on-Demand, Applied Biosystems, Foster City, CA, USA). The total reaction volume was 10 μL. Each reaction was carried out in triplicate on 384 well plates. Relative gene expression was calculated using the comparative CT method. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was used as the internal control.
Statistical analysis
Continuous variables were compared between patients with OSA and control participants using Mann-Whitney test. Unconditional logistic regression analysis was per- formed to calculate odds ratios (ORs) and 95% confidence intervals (CIs), with adjustment for possible confounders (sex as a nominal variable and age as a continuous variable). All analyses were performed using Statistical Analysis Software for Windows, version 8.12 (SAS Institute, Cary, NC, USA).
RESULTS
Samples from six patients with OSA and three nonapneic control participants were chosen for microarray analysis and the corresponding data were used as the training set. The demographic characteristics of these participants are summarized in Table 1 Of the 14,210 genes assessed, the expression of 343 was found to be significantly different in PBMCs between patients with OSA and nonapneic control participants (data not shown). The threshold of significance was taken as a twofold up-or down-regulation because a previous study demonstrated that changes in PBMC gene expression in peripheral blood are generally minor, except those in response to infectious diseases. [34] The differentially expressed genes were categorized using Gene-Ontology; 76, 53, and 47 genes were identified to be involved in biological processes, cellular components, and molecular function, respectively [ Table 2 ]. The four most differentially expressed processes in the category of biological processes in patients with OSA involved cellular physiological processes (17 up-regulated genes and 7 down-regulated genes), metabolism, cell communication, and response to stimuli [ Table 2 ]. Interestingly, in categorizing these differential expressed genes by their molecular functions, we found that hydrolase activity, nucle- To further systematically analyze these differentially expressed genes using MetaCore (GeneGo, St Joseph, MI, USA), 56 genes (with > 2-fold changes and p < 0.05) were categorized into 19 known or probable functional pathways [ Table 3 ]. Among these pathways, several intracellular signaling cascades were identified that may be involved in the pathogenesis of OSA, including G-protein coupled receptor signaling pathways, transforming growth factor-β (TGF-β) receptor signaling pathways, and cell surface linked signal transduction pathways [ Table 3 ]. Expression of genes in pathways involving chromatin remodeling [ Table 3 ] was also altered in patients with OSA, suggesting that global transcriptome alterations in PBMCs might be due to global epigenetic modifications [ Table 3 ]. Expression of genes in other pathways involved in cell adhesion, DNA replication, and positive regulation of T cell activation was also found to be altered in patients with OSA [ Table 3 ].
After performing global analysis to identify the functional pathways potentially involved in OSA pathogenesis, we examined whether the identified differentially expressed genes could be used as markers of OSA in Asian patients. As illustrated in Figure 1 and Table 4 , several of the top 30 genes identified to have altered regulation were not previously found to be associated with OSA, particularly in the PBMC transcriptome. A disintegrin and metalloproteinase domain 29 (ADAM29) and immunoglobulin superfamily, member 2 (IGSF2) were the most significantly up-regulated (7.6-fold) and down-regulated (fourfold) genes in patients with OSA compared with control participants.
To confirm the microarray data in this training set, the expression levels of six genes were analyzed using RTQ-PCR (the candidate genes were determined on the basis of the fold change). The expression levels of ADAM29, fibronectin-like domain-containing leucine-rich transmembrane protein 2 (FLRT2), solute carrier family 18 (vesicular acetylcholine) member 3 (SLC18A3), cyclin-dependent kinase inhibitor 2C (CDKN2C), and matrix metallopeptidase 14 (membrane-inserted) (MMP14) were consistent with the microarray data, whereas the expression of peroxisomal trans-2-enoyl-CoA reductase (HSA250303) was not obviously decreased as determined by real-time PCR [ Table 5 ].
To further confirm the microarray data, 25 patients with OSA and 24 nonapneic control participants were used as a validation set to analyze expression of these six genes. The mean age of the nonapneic control participants was 32.8 ± 11.3 years (range: 21-63 years), whereas the mean age of the patients with OSA was 44.8 ± 9.8 years (range: 32-69 years) [ Table 6 ]. The mean BMI was 21.8 ± 2.2 kg/m 2 for control participants and 26.5 ± 3.5 kg/m 2 for patients with OSA (p < 0.001), whereas the corresponding mean RDI was 0.6 ± 0.9 and 41.9 ± 26.7, respectively (p < 0.001) [ Table 6 ]. The comparison between participants in the training set and the validation set is shown in Table 7 . As shown in Figure 2 , the expression levels of ADAM29 (p = 0.0003), SLC18A3 (p = 0.0006), and FLRT2 (p < 0.0001) were significantly different between patients with severe OSA (RDI ≥ 30) and patients with mild OSA and control participants (RDI < 30). There were no differences in the expression levels of ADAM29 and SLC18A3 between patients with mild OSA and control participants (p = 0.62 and 0.10, respectively). The different FLRT2 expression levels between mild OSA and control subjects was borderline significant (p = 0.046). Expression of CDKN2C was significantly different between patients with mild OSA and control participants (p = 0.01); however, there was no difference between patients with severe OSA and control participants (p = 0.064). There were no significant differences in expression of HSA250303 (p = 0.45) or MMP14 (p = 0.064) in the validation set [ Figure 2 ]. Our data show that there were significant differences in the expression of three genes (ADAM29, SLC18A3, and FLRT2) between patients with severe OSA (RDI < 30) and patients with mild OSA and control participants.
DISCUSSION
In this study, we firstly characterized the global gene expression profile in peripheral blood obtained from Asian adults with OSA. Our results suggest that genes involving in cell adhesion, cell communication, and receptor signaling are differentially expressed in patients with severe OSA compared with nonapneic control individuals. The specific genes found to be differentially expressed were ADAM29, FLRT2, and SLC18A3.
ADAM29 has been cloned and mapped to human chromosome 4. Findings from a previous study revealed that ADAM29 was highly expressed in testis, but only slightly or not at all expressed in the other 15 human tissues tested using Northern blotting. [35] A recent report suggested that ADAM29 gene expression may be a strong prognostic indicator in patients with chronic lymphocytic leukemia (CML). [36] This finding suggests that ADAM29 may be expressed in other tissues in certain conditions, such as cancer cells under hypoxia in patients with CML.
To our knowledge, there have been no reports to date describing expression of the ADAM29 gene in PBMCs from patients with OSA. It is unclear whether expression of ADAM29 will be activated or if a certain proportion of cells in peripheral blood will be increased in response to the intermittent hypoxia/reoxygenation that occurs with OSA. The ADAM family gene products are involved in a highly diverse set of biological processes, including fertilization, neurogenesis, myogenesis, embryonic TGF-β release, and inflammatory responses. [37] The findings from several reports indicate that chronic inflammation occurs in patients with OSA; hence, we suggest that the existence of a chronic inflammatory status in patients with OSA may have induced the differential gene expression observed in our study. This possibility is supported by the identification of several inflammatory pathways using MetaCore analysis, specifically TGF-β signaling and G-protein coupled receptor signaling.
Further studies are needed to elucidate the potential relationship between inflammatory pathways and ADAM29. FLRT2 is widely expressed in human tissues, with particularly high expression levels found in ovaries and relatively high expression levels found in the brain, skeletal muscle, heart, and pancreas. [38] Findings from a previous study indicate that FLRT2 plays a role in cell adhesion and FGF receptor signaling, and that FLRT2 contains leucine-rich repeats (LRRs), which have a diverse range of functions. [38] LRRs provide a structural framework for the formation of protein-protein interactions, including with GTPase-activating protein rna1p, spliceosomal protein U2A', Rab geranylgeranyltransferase, internalin B, dynein light chain 1 and nuclear export protein TAP, and Skp2. [39] We found gene transcript levels of FLRT2 were significantly depressed in patients with severe OSA compared with nonapneic control participants and patients with mild OSA. It is possible that intermittent hypoxia/reoxygenation, sleep fragmentation, or sympathetic activation resulted in disruption or inhibition of FLRT2 protein complexes, which in turn may have resulted in decreased downstream signaling in patients with severe OSA.
Vesicular acetylcholine transporter (VAChT, SLC18A3) exchanges luminal protons for cytoplasmic acetylcholine to drive the storage of acetylcholine. [40] The distribution of SLC18A3 mRNA in the peripheral and central cholinergic nervous systems coincides with that of choline acetyltransferase (ChAT), the enzyme required for acetylcholine biosynthesis. [41] Human SLC18A3 cDNA was used to localize the SLC18A3 gene to chromosome 10q11.2, which is also where the ChAT gene is located. [41] Northern blot analysis has demonstrated that this sequence is expressed in the basal forebrain, basal ganglia, and spinal cord, but not the cerebellum or peripheral tissues. In situ hybridization has demonstrated the expression of SLC18A3 mRNA in all cholinergic cell groups previously reported to express choline acetyltransferase mRNA, including those in the basal forebrain, brainstem, and spinal cord. [42] The biological func- tion of SLC18A3 remains to be determined. Our finding that SLC18A3 gene expression was significantly up-regulated in peripheral blood from patients with OSA highlights the possibility that cholinergic degeneration may be involved in mediating the impaired cognitive function in patients with OSA; however, further studies are clearly need to explore this possibility. The protein encoded by cyclin-dependent kinase inhibitor 2C (CDKN2C, INK4C, p18) has been shown to interact with CDK4 and CDK6. Further, ectopic expression of CDKN2C correlates with the presence of wild-type Rb1 and suppresses the growth of human cells. [43] There is evidence to suggest that inactivation of CDKN2C, because of point mutations, may contribute to deregulated growth in certain cell lines and/or tumors. [44] Using reconstituted mice with CDKN2C-deficient hematopoietic cells and in vivo evaluation of stem cell function, CDKN2C was found to inhibit cell division in hematopoietic stem cells and early hematopoietic progenitor cells. [45] Most of the studies conducted to date involving CDKN2C have focused on tumor cells, but the findings from mutational analysis in sporadic pancreatic endocrine tumors argue against CDKN2C having a tumor-suppressing function. [46] In a previous study, transfer of CDKN2C genes into rheumatoid arthritis synovial fibroblasts was found to suppress the production of matrix metalloproteinase-3 and monocyte chemotactic protein-1. [47] These results show that cell cycle proteins play a role in regulating the expression of inflammatory mediators. In the present study, we found that CDKN2C was differentially expressed between patients with mild OSA and control group participants; however, there was no difference in expression between patients with severe OSA and the control group participants. This discordance is a reflection of the widely distributed data in the group of patients with severe OSA. Therefore, we plan to collect additional samples to further compare the expression of CDKN2C between patients with OSA and nonapneic control participants.
A previous study used HG-U133A and B arrays (Affymetrix) to analyze genomic oxidative stress and cell cycle responses in peripheral blood from adults with OSA. [28] The authors of the study found that there were significant changes in the expression of several genes involved in modulation of ROS, cell growth, proliferation, and the cell cycle (e.g., cell division cycle 25B, signaling lymphocyte activating molecule, calgizzarin S100A11, B-cell translocation gene, Src-like adapter protein, and eukaryotic translation initiation factor 4E binding protein 2). [28] These results are different from ours, perhaps reflecting differences in race/ethnicity. Our patients with OSA had lower BMI (26.9 ± 4.2 vs. 35.5 ± 1.29), despite having similar RDI severity (42.9 ± 28.9 vs. 50.2 ± 23.5). Differences in race may have resulted in different gene expression profiles in the peripheral blood obtained from patients with OSA. In another study, gene expression profiling in non-obese children with OSA was also performed using microarray. [29] The authors identified significant changes in three genes, malonyl-CoA and a mitochondrial acyl carrier protein, serine 36 protease, and interleukin 27. The findings from this study are different from the aforementioned findings [28] and, indeed, our own findings. This may be because the majority of pediatric patients with OSA have adenoid/tonsillar hypertrophy, whereas the population of adults with OSA is heterogenous. The etiology of pediatric and adult OSA is different; hence, it is difficult to compare microarray results, even if the same microarray platform is used.
Our study has two limitations that warrant mention. The first limitation concerns the control of sex and BMI. Participants enrolled in the training and validation sets were not sex-or BMI-matched; hence, the observed differential expression of our candidate genes may have been confounded to some extent by sex and obesity. The second limitation concerns the generalizablity of our findings. We suggest that our findings may not be broadly generalizable because of the limited number of individuals included in the study.
In summary, we have used microarray analysis to search for genes potentially involved in the pathogenesis of OSA. We detected changes in gene patterns in PBMCs obtained from patients with severe OSA as compared with normal control participants and patients with mild OSA. Patients with severe OSA may have a higher risk of developing cardiovascular disease or stroke; hence, aggressive treatment or intensive care may be warranted. Early diagnosis and aggressive treatment will help prevent disease progression. We identified potential markers of OSA in a small Asian population. These markers may be useful to routinely screen individuals and identify those at risk of severe OSA. Further study of these markers and their potential applicability for the screening of OSA is warranted in larger populations.
